| Name | Hale Makua - Kahului |
|---|---|
| Location | 472 Kaulana Street, Kahului, Hawaii |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 254 |
| Occupancy Rate | 77.8% |
| Medicare ID (CCN) | 125007 |
| Legal Business Name | Hale Makua Health Services |
| Ownership Type | Non Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
"Efforts to build resilience in the Sahel, a region chronically affected by drought and malnutrition, are highly fragmented, dysfunctional and ineffective, a report from Save the Children and World Vision said on Wednesday," the Guardian reports.
A Clinical Perspectives article published in the November 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry proposes a tool to empower stakeholders, guide caregivers, and provide a rationale for advocates, when considering the systems of support offered to people with an autism spectrum disorder (ASD).
Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.67 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.71 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.49 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.4 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.48 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.09 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.48 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.26 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.72 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 51.16 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.59 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.47 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 7.32 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.85 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.34 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 67.02 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 59.69 | 82.93 |
News Archive
"Efforts to build resilience in the Sahel, a region chronically affected by drought and malnutrition, are highly fragmented, dysfunctional and ineffective, a report from Save the Children and World Vision said on Wednesday," the Guardian reports.
A Clinical Perspectives article published in the November 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry proposes a tool to empower stakeholders, guide caregivers, and provide a rationale for advocates, when considering the systems of support offered to people with an autism spectrum disorder (ASD).
Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
› Verified 5 days ago